YING YUAN to Maximum Tolerated Dose
This is a "connection" page, showing publications YING YUAN has written about Maximum Tolerated Dose.
Connection Strength
2.720
-
Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Stat Med. 2015 May 10; 34(10):1681-94.
Score: 0.402
-
Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clin Trials. 2014 06; 11(3):319-327.
Score: 0.384
-
Bayesian hybrid dose-finding design in phase I oncology clinical trials. Stat Med. 2011 Jul 30; 30(17):2098-108.
Score: 0.306
-
Sequential continual reassessment method for two-dimensional dose finding. Stat Med. 2008 Nov 29; 27(27):5664-78.
Score: 0.262
-
TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Stat Med. 2022 05 20; 41(11):1918-1931.
Score: 0.163
-
Incorporating historical information to improve phase I clinical trials. Pharm Stat. 2021 11; 20(6):1017-1034.
Score: 0.154
-
Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. Contemp Clin Trials. 2021 05; 104:106338.
Score: 0.153
-
Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. Biostatistics. 2020 10 01; 21(4):807-824.
Score: 0.149
-
A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. Stat Med. 2019 12 10; 38(28):5299-5316.
Score: 0.139
-
On the relative efficiency of model-assisted designs: a conditional approach. J Biopharm Stat. 2019; 29(4):648-662.
Score: 0.136
-
Comparative review of novel model-assisted designs for phase I clinical trials. Stat Med. 2018 06 30; 37(14):2208-2222.
Score: 0.126
-
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res. 2016 Sep 01; 22(17):4291-301.
Score: 0.111
-
The continual reassessment method for multiple toxicity grades: a bayesian model selection approach. PLoS One. 2014; 9(5):e98147.
Score: 0.096
-
A latent contingency table approach to dose finding for combinations of two agents. Biometrics. 2009 Sep; 65(3):866-75.
Score: 0.064
-
AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials. Pharm Stat. 2023 03; 22(2):300-311.
Score: 0.043
-
Accuracy, Safety, and Reliability of Novel Phase I Trial Designs. Clin Cancer Res. 2018 09 15; 24(18):4357-4364.
Score: 0.031